HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Manufacturing Updates in Brief

This article was originally published in The Gold Sheet

Executive Summary

GMP issues delayed Boehringer launch; Nigerian firms meet WHO GMPs; Novartis closing Puerto Rico plant; Hospira closing Clayton site; Valeant looks to move Bausch + Lomb manufacturing abroad; these IV bags were training aides.

You may also be interested in...



Striverdi Respimat Clinical Development

A timeline chronicling the development of Boehringer Ingelheim’s chronic obstructive pulmonary disease treatment olodaterol.

Novel COPD Exercise Claims Eluded Boehringer In Bid to Differentiate Striverdi

Sponsor’s claimed impact on exercise tolerance was not adequately supported and should not serve as a marketing advantage for the chronic obstructive pulmonary disease drug, FDA review staff said. However, Boehringer Ingelheim’s failed attempt for the exercise-related labeling language spurred the agency to clarify the types of studies and endpoints that potentially could support such claims.

Minute Insight: Viagra May Face Stiff US Competition From Futura’s Gel-Based Device

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS123618

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel